Anti-CD33/ SIGLEC-3/ SIGLEC3 monoclonal antibody

Anti-CD33/ SIGLEC-3/ SIGLEC3 antibody for FACS & in-vivo assay

Target products collectionGo to CD33/CD33 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T38950-Ab-1/ GM-Tg-hg-T38950-Ab-2Anti-Human CD33 monoclonal antibodyHuman
GM-Tg-rg-T38950-Ab-1/ GM-Tg-rg-T38950-Ab-2Anti-Rat CD33 monoclonal antibodyRat
GM-Tg-mg-T38950-Ab-1/ GM-Tg-mg-T38950-Ab-2Anti-Mouse CD33 monoclonal antibodyMouse
GM-Tg-cynog-T38950-Ab-1/ GM-Tg-cynog-T38950-Ab-2Anti-Cynomolgus/ Rhesus macaque CD33 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T38950-Ab-1/ GM-Tg-felg-T38950-Ab-2Anti-Feline CD33 monoclonal antibodyFeline
GM-Tg-cang-T38950-Ab-1/ GM-Tg-cang-T38950-Ab-2Anti-Canine CD33 monoclonal antibodyCanine
GM-Tg-bovg-T38950-Ab-1/ GM-Tg-bovg-T38950-Ab-2Anti-Bovine CD33 monoclonal antibodyBovine
GM-Tg-equg-T38950-Ab-1/ GM-Tg-equg-T38950-Ab-2Anti-Equine CD33 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T38950-Ab-1/ GM-Tg-hg-T38950-Ab-2; GM-Tg-rg-T38950-Ab-1/ GM-Tg-rg-T38950-Ab-2;
GM-Tg-mg-T38950-Ab-1/ GM-Tg-mg-T38950-Ab-2; GM-Tg-cynog-T38950-Ab-1/ GM-Tg-cynog-T38950-Ab-2;
GM-Tg-felg-T38950-Ab-1/ GM-Tg-felg-T38950-Ab-2; GM-Tg-cang-T38950-Ab-1/ GM-Tg-cang-T38950-Ab-2;
GM-Tg-bovg-T38950-Ab-1/ GM-Tg-bovg-T38950-Ab-2; GM-Tg-equg-T38950-Ab-1/ GM-Tg-equg-T38950-Ab-2
Products NameAnti-CD33 monoclonal antibody
Formatmab
Target NameCD33
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD33 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-607Pre-Made Vadastuximab biosimilar, Whole mAb ADC, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
    BiosimilarGMP-Bios-INN-717Pre-Made Actinium (225Ac) Lintuzumab Satetraxetan Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-314Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
    BiosimilarGMP-Bios-ab-176Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-624Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibody
    BiosimilarGMP-Bios-INN-1042Pre-Made Vadastuximab Talirine Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-239Pre-Made Gemtuzumab biosimilar, Whole mAb ADC, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
    BiosimilarGMP-Bios-INN-855Pre-Made Gemtuzumab Ozogamicin Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-ab-173Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species CD33/ SIGLEC-3/ SIGLEC3 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMLP004251human CD33 Lentivirus plasmid
    ORF Viral VectorvGMLP004251human CD33 Lentivirus particle
    ORF Viral VectorpGMLPm003482mouse Cd33 Lentivirus plasmid
    ORF Viral VectorvGMLPm003482mouse Cd33 Lentivirus particle


    Target information

    Target IDGM-T38950
    Target NameCD33
    Gene ID945,12489,719855
    Gene Symbol and SynonymsCD33,gp67,p67,SIGLEC-3,SIGLEC3
    Uniprot AccessionP20138
    Uniprot Entry NameCD33_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000105383
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: CD33, gene name: CD33, also named as SIGLEC-3, SIGLEC3, p67. Enables protein phosphatase binding activity and sialic acid binding activity. Involved in several processes, including negative regulation of cytokine production; negative regulation of monocyte activation; and positive regulation of protein tyrosine phosphatase activity. Located in several cellular components, including Golgi apparatus; external side of plasma membrane; and peroxisome. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.